Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer

TY - JOUR

T1 - Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer

AU - Kümler, Iben

AU - Parner, Vibeke Kirk

AU - Tuxen, Malgorzata K.

AU - Skjoldbye, Bjørn

AU - Bergenfeldt, Magnus

AU - Nelausen, Knud Mejer

AU - Nielsen, Dorte Lisbet

PY - 2015/6/22

Y1 - 2015/6/22

N2 - PURPOSE: Despite improved anti-neoplastic treatment the prognosis for patients with liver metastases from metastatic breast cancer remains poor.MATERIALS AND METHODS: Thirty-two consecutive patients with metastatic breast cancer treated with radiofrequency ablation (RFA) at the Department of Oncology, Herlev Hospital, University of Copenhagen, from 1996 to 2010.RESULTS: Time to intrahepatic progression was median 11 months (range 1.6-184 months). Median survival after first RFA was 33.5 months. Survival at 1, 2 and 3 years was 87, 68 and 48 %, respectively. The local recurrence rate was 22 %.CONCLUSIONS: In this small, highly selected cohort we found RFA safe and efficacious with a low local recurrence rate and a median survival above that expected with systemic treatment. Our data are in line with previous studies and underscore the need for a large prospective study using optimal chemotherapy regimens and RFA/surgery to clarify whether intense treatment protocols can prolong survival for certain patient groups.

AB - PURPOSE: Despite improved anti-neoplastic treatment the prognosis for patients with liver metastases from metastatic breast cancer remains poor.MATERIALS AND METHODS: Thirty-two consecutive patients with metastatic breast cancer treated with radiofrequency ablation (RFA) at the Department of Oncology, Herlev Hospital, University of Copenhagen, from 1996 to 2010.RESULTS: Time to intrahepatic progression was median 11 months (range 1.6-184 months). Median survival after first RFA was 33.5 months. Survival at 1, 2 and 3 years was 87, 68 and 48 %, respectively. The local recurrence rate was 22 %.CONCLUSIONS: In this small, highly selected cohort we found RFA safe and efficacious with a low local recurrence rate and a median survival above that expected with systemic treatment. Our data are in line with previous studies and underscore the need for a large prospective study using optimal chemotherapy regimens and RFA/surgery to clarify whether intense treatment protocols can prolong survival for certain patient groups.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Breast Neoplasms

KW - Catheter Ablation

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Liver Neoplasms

KW - Middle Aged

KW - Treatment Outcome

U2 - 10.1007/s11547-014-0489-6

DO - 10.1007/s11547-014-0489-6

M3 - Journal article

C2 - 25572543

SN - 0033-8362

VL - 120

SP - 536

EP - 541

JO - La Radiologia Medica

JF - La Radiologia Medica

IS - 6

ER -